|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 RAs have an overall neutral effect on HF outcomes.
|
31816162 |
2020 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The benefits with GLP-1 RAs are most likely derived through the reduction of atherosclerosis-related events while SGLT-2is seem mostly to reduce heart failure-related events.
|
31778747 |
2020 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In primary prevention, SGLT-2i reduce both the risk of hospitalization for HF and progression of DKD; in secondary prevention, SGLT-2i are effective on the three endpoints, DPP-4i are neutral, while GLP1-RA show mixed results.
|
31495989 |
2020 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In T2D, SGLT-2i can reduce the risk of HF that is unrelated to improved glycemic control; DPP-4i and GLP-1 RAs behave as neutral.
|
31028667 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acute infusion of GLP-1 has a neutral hemodynamic effect, when assessed by thermodilution, in patients with heart failure.
|
30598343 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
While dipeptidyl peptidase-4 (DPP-4) inhibitors exhibited increased heart failure hospitalization in the SAVOR-TIMI 53 trial evaluating saxagliptin and in the secondary analysis of the EXAMINE trial for alogliptin, the effects of glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter-2 (SGLT2) inhibitors on CV outcomes in diabetes have largely been positive.
|
30767126 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In comparison, GLP-1 RA appear to preferentially reduce ischemic events (stroke or myocardial infarction) over hospitalization for heart failure, and demonstrated renoprotection in several of the CVOTs.
|
31436559 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
New medication classes, like glucagon-like peptide 1 (GLP-1) analogues and sodium-glucose co-transporter 2 (SGLT2) inhibitors, have shown reductions in the risk of major adverse cardiovascular events (MACE) including, myocardial infarction, stroke, CV death, and heart failure (HF).
|
31442511 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SGLT-2 inhibitors and GLP-1 RAs significantly reduced MACE (OR 0.88, 95% CI 0.82-0.95 and OR 0.87, 95% CI 0.82-0.93), hospitalisation for HF (OR 0.68, 95% CI 0.61-0.77 and OR 0.87, 95% CI 0.82-0.93), and renal composite outcome (OR 0.59, 95% CI 0.52-0.67 and OR 0.86, 95% CI 0.78-0.94) compared to placebo, but SGLT-2 inhibitors reduced hospitalisation for HF (OR 0.79, 95% CI 0.69-0.90) and renal composite outcome (OR 0.69, 95% CI 0.59-0.80) more than GLP-1 RAs.
|
31462224 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Five completed CVOTs with the GLP-1 RAs lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), exenatide once weekly (EXSCEL) and albiglutide (HARMONY) also failed to reveal any significant effect on HF risk.
|
30609236 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists are two anti-hyperglycemic classes which have been of special interest after multiple large cardiovascular disease (CVD) outcomes studies have demonstrated superiority of these agents compared to placebo for major adverse CVD events and in some cases, hospitalization for heart failure.
|
31381891 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide (GLP-1) is a naturally occurring incretin used as a promising therapeutic agent in the treatment of acute myocardial infarction, dilated cardiomyopathy, and advanced heart failure.
|
30503377 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased intestinal GLP-1 secretion is an adaptive response to heart failure that is enhanced by miglitol.
|
30629149 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SGLT2i reduced hospitalization for heart failure by 31% (HR, 0.69; 95% CI, 0.61-0.79; P<0.001), whereas GLP1-RA did not have a significant effect (HR, 0.93; 95% CI, 0.83-1.04; P=0.20).
|
30786725 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy.
|
31779634 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Such CVOTs have demonstrated that the effects of the new antidiabetic drugs on the mutual interactions between T2DM and HF may develop across different phases:Results of such trials can be summarized as: (a) all different classes of novel glucose-lowering drugs have good cardiovascular safety profile; (b) with respect to HF, DPP4 inhibitors might tend to increase risk; (c) sodium-glucose co-transporter 2 inhibitors (SGTLi), significantly reduce it; (d) glucagon-like peptide 1 receptor agonists (GLP1) tend to be neutral.
|
31479706 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
There are concerns that incretin-based antidiabetic drugs - including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists - increase the risk of hospitalization for heart failure (HF).
|
30332619 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prior studies with DPP-IV inhibitors, thiazolidinediones (TZDs), and GLP-1 agonists have demonstrated either a neutral effect on HF or increased HF hospitalizations.
|
30259198 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cox proportional hazards models with propensity-score-matching were used to compare the risk of HF hospitalization between DPP-4 inhibitors and GLP-1 agonists.
|
30016946 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although glucagon (S-W) showed no significant difference in patients with and without HF, especially reduced LVEF, glucagon (RIA) secretion was significantly lower in HF patients than in patients without HF.
|
30213772 |
2018 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Current evidence suggests that SGLT-2 inhibitors are more effective than either GLP-1 agonists or DPP-4 inhibitors for reducing the risk of hospitalization for HF in type 2 diabetes mellitus.
|
30196071 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The glucagon-like peptide-1 (GLP-1) agonists, liraglutide and semaglutide, have been shown to reduce major CV events, but did not affect rates of hospitalization for HF.
|
29270818 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure.
|
29805980 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of neprilysin in the metabolism of endogenous GLP-1 and long-acting GLP-1 analogues points to a range of potential pathophysiological effects that may be clinically relevant to patients with heart failure, with or without diabetes.
|
29603541 |
2018 |